Use of intravenous bisphosphonates in older women with breast cancer

Sharon H. Giordano, Shenying Fang, Zhigang Duan, Yong Fang Kuo, Gabriel N. Hortobagyi, James Goodwin

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Introduction. i.v. bisphosphonates reduce skeletal events in women with bone metastases from breast cancer, but little is known about the prevalence and duration of bisphosphonate use. Methods. Patients were identified from the Surveillance, Epidemiology, and End Results-Medicare database who were aged ≥65 years and were diagnosed with invasive breast cancer in 1995-2002. Healthcare Common Procedure Coding System codes were used to identify patients treated with pamidronate and zoledronic acid. Descriptive statistics were used to describe patterns of use. Multivariate analyses were performed to determine the predictors of bisphosphonate use. Results. In total, 55,864 women with breast cancer were included, with 307,467 person-years of follow-up. Overall, 1.26% of women with all stages of breast cancer received i.v. bisphosphonates. In 2004, 2% of all breast cancer patients and 32% of patients with distant stage disease received bisphosphonates. Approximately two thirds of patients treated with bisphosphonates received zoledronic acid and one third received pamidronate in 2004. Multivariate analyses showed that patients who were ≥75 years old were less likely to receive bisphosphonates (75-79 years versus 65-69 years: odds ratio [OR], 0.81; 95% confidence interval [CI], 0.70-0.93; 80+ years versus 65-69 years: OR, 0.49; 95% CI, 0.42-0.57). The use of bisphosphonates dramatically increased over time. The majority of living patients were continued on i.v. bisphosphonates once started (83% at 1 year, 64% at 3 years, 50% at 5 years), but the median survival time after initiation of i.v. bisphosphonates was only 21 months. Conclusions. i.v. bisphosphonates appear to be under-used in patients with metastatic breast cancer, particularly among those patients >75 years of age.

Original languageEnglish (US)
Pages (from-to)494-502
Number of pages9
JournalOncologist
Volume13
Issue number5
DOIs
StatePublished - May 2008

Fingerprint

Diphosphonates
Breast Neoplasms
zoledronic acid
pamidronate
Healthcare Common Procedure Coding System
Multivariate Analysis
Odds Ratio
Confidence Intervals
Medicare
Epidemiology
Databases
Neoplasm Metastasis
Bone and Bones

Keywords

  • Breast cancer
  • Elderly
  • Metastatic

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Use of intravenous bisphosphonates in older women with breast cancer. / Giordano, Sharon H.; Fang, Shenying; Duan, Zhigang; Kuo, Yong Fang; Hortobagyi, Gabriel N.; Goodwin, James.

In: Oncologist, Vol. 13, No. 5, 05.2008, p. 494-502.

Research output: Contribution to journalArticle

Giordano, Sharon H. ; Fang, Shenying ; Duan, Zhigang ; Kuo, Yong Fang ; Hortobagyi, Gabriel N. ; Goodwin, James. / Use of intravenous bisphosphonates in older women with breast cancer. In: Oncologist. 2008 ; Vol. 13, No. 5. pp. 494-502.
@article{3eaf97d4f45a4b45b9154fde8ee8991f,
title = "Use of intravenous bisphosphonates in older women with breast cancer",
abstract = "Introduction. i.v. bisphosphonates reduce skeletal events in women with bone metastases from breast cancer, but little is known about the prevalence and duration of bisphosphonate use. Methods. Patients were identified from the Surveillance, Epidemiology, and End Results-Medicare database who were aged ≥65 years and were diagnosed with invasive breast cancer in 1995-2002. Healthcare Common Procedure Coding System codes were used to identify patients treated with pamidronate and zoledronic acid. Descriptive statistics were used to describe patterns of use. Multivariate analyses were performed to determine the predictors of bisphosphonate use. Results. In total, 55,864 women with breast cancer were included, with 307,467 person-years of follow-up. Overall, 1.26{\%} of women with all stages of breast cancer received i.v. bisphosphonates. In 2004, 2{\%} of all breast cancer patients and 32{\%} of patients with distant stage disease received bisphosphonates. Approximately two thirds of patients treated with bisphosphonates received zoledronic acid and one third received pamidronate in 2004. Multivariate analyses showed that patients who were ≥75 years old were less likely to receive bisphosphonates (75-79 years versus 65-69 years: odds ratio [OR], 0.81; 95{\%} confidence interval [CI], 0.70-0.93; 80+ years versus 65-69 years: OR, 0.49; 95{\%} CI, 0.42-0.57). The use of bisphosphonates dramatically increased over time. The majority of living patients were continued on i.v. bisphosphonates once started (83{\%} at 1 year, 64{\%} at 3 years, 50{\%} at 5 years), but the median survival time after initiation of i.v. bisphosphonates was only 21 months. Conclusions. i.v. bisphosphonates appear to be under-used in patients with metastatic breast cancer, particularly among those patients >75 years of age.",
keywords = "Breast cancer, Elderly, Metastatic",
author = "Giordano, {Sharon H.} and Shenying Fang and Zhigang Duan and Kuo, {Yong Fang} and Hortobagyi, {Gabriel N.} and James Goodwin",
year = "2008",
month = "5",
doi = "10.1634/theoncologist.2007-0200",
language = "English (US)",
volume = "13",
pages = "494--502",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "5",

}

TY - JOUR

T1 - Use of intravenous bisphosphonates in older women with breast cancer

AU - Giordano, Sharon H.

AU - Fang, Shenying

AU - Duan, Zhigang

AU - Kuo, Yong Fang

AU - Hortobagyi, Gabriel N.

AU - Goodwin, James

PY - 2008/5

Y1 - 2008/5

N2 - Introduction. i.v. bisphosphonates reduce skeletal events in women with bone metastases from breast cancer, but little is known about the prevalence and duration of bisphosphonate use. Methods. Patients were identified from the Surveillance, Epidemiology, and End Results-Medicare database who were aged ≥65 years and were diagnosed with invasive breast cancer in 1995-2002. Healthcare Common Procedure Coding System codes were used to identify patients treated with pamidronate and zoledronic acid. Descriptive statistics were used to describe patterns of use. Multivariate analyses were performed to determine the predictors of bisphosphonate use. Results. In total, 55,864 women with breast cancer were included, with 307,467 person-years of follow-up. Overall, 1.26% of women with all stages of breast cancer received i.v. bisphosphonates. In 2004, 2% of all breast cancer patients and 32% of patients with distant stage disease received bisphosphonates. Approximately two thirds of patients treated with bisphosphonates received zoledronic acid and one third received pamidronate in 2004. Multivariate analyses showed that patients who were ≥75 years old were less likely to receive bisphosphonates (75-79 years versus 65-69 years: odds ratio [OR], 0.81; 95% confidence interval [CI], 0.70-0.93; 80+ years versus 65-69 years: OR, 0.49; 95% CI, 0.42-0.57). The use of bisphosphonates dramatically increased over time. The majority of living patients were continued on i.v. bisphosphonates once started (83% at 1 year, 64% at 3 years, 50% at 5 years), but the median survival time after initiation of i.v. bisphosphonates was only 21 months. Conclusions. i.v. bisphosphonates appear to be under-used in patients with metastatic breast cancer, particularly among those patients >75 years of age.

AB - Introduction. i.v. bisphosphonates reduce skeletal events in women with bone metastases from breast cancer, but little is known about the prevalence and duration of bisphosphonate use. Methods. Patients were identified from the Surveillance, Epidemiology, and End Results-Medicare database who were aged ≥65 years and were diagnosed with invasive breast cancer in 1995-2002. Healthcare Common Procedure Coding System codes were used to identify patients treated with pamidronate and zoledronic acid. Descriptive statistics were used to describe patterns of use. Multivariate analyses were performed to determine the predictors of bisphosphonate use. Results. In total, 55,864 women with breast cancer were included, with 307,467 person-years of follow-up. Overall, 1.26% of women with all stages of breast cancer received i.v. bisphosphonates. In 2004, 2% of all breast cancer patients and 32% of patients with distant stage disease received bisphosphonates. Approximately two thirds of patients treated with bisphosphonates received zoledronic acid and one third received pamidronate in 2004. Multivariate analyses showed that patients who were ≥75 years old were less likely to receive bisphosphonates (75-79 years versus 65-69 years: odds ratio [OR], 0.81; 95% confidence interval [CI], 0.70-0.93; 80+ years versus 65-69 years: OR, 0.49; 95% CI, 0.42-0.57). The use of bisphosphonates dramatically increased over time. The majority of living patients were continued on i.v. bisphosphonates once started (83% at 1 year, 64% at 3 years, 50% at 5 years), but the median survival time after initiation of i.v. bisphosphonates was only 21 months. Conclusions. i.v. bisphosphonates appear to be under-used in patients with metastatic breast cancer, particularly among those patients >75 years of age.

KW - Breast cancer

KW - Elderly

KW - Metastatic

UR - http://www.scopus.com/inward/record.url?scp=45749147918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45749147918&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2007-0200

DO - 10.1634/theoncologist.2007-0200

M3 - Article

C2 - 18515734

AN - SCOPUS:45749147918

VL - 13

SP - 494

EP - 502

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 5

ER -